Showing 1 - 8 of 8 Items
Showing 1 - 8 of 8 Items
Sort By: Relevance
Journal Article
|Research
2025-01-29 • New England Journal of Medicine
2025-01-29 • New England Journal of Medicine
BACKGROUND
For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs ...
Journal Article
|Research
2024-01-29 • medRxiv
2024-01-29 • medRxiv
BACKGROUND
Aft...
Journal Article
|Research
2024-01-20 • medRxiv
2024-01-20 • medRxiv
RATIONALE
Treatment outcomes may be compromised among patients with multidrug- or rifampicin-resistant tuberculosis with additional fluoroquinolone resis...
Journal Article
|Research
2022-09-15 • Clinical Infectious Diseases
2022-09-15 • Clinical Infectious Diseases
RATIONALE
Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an obstacle to treatment completion.
OBJECTIVES
Evaluate safety of longer MDR/RR-TB...
Safety of treatment for multidrug-resistant tuberculosis (MDR/RR-TB) can be an obstacle to treatment completion.
OBJECTIVES
Evaluate safety of longer MDR/RR-TB...
Journal Article
|Research
2022-06-21 • Public Health Action
2022-06-21 • Public Health Action
BACKGROUND
Direct-acting antivirals (DAAs) are not widely used for patients with chronic hepatitis C virus (HCV) infection and multidrug- or rifampicin-resistant TB (MDR/RR-TB). We d...
Direct-acting antivirals (DAAs) are not widely used for patients with chronic hepatitis C virus (HCV) infection and multidrug- or rifampicin-resistant TB (MDR/RR-TB). We d...
Journal Article
|Research
2018-07-01 • International Journal of Tuberculosis and Lung Disease
2018-07-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND AND SETTING
Bedaquiline (BDQ) was initially only available through compassionate use programmes.
OBJECTIVE
To assess the effectiveness and safety of multidrug...
Bedaquiline (BDQ) was initially only available through compassionate use programmes.
OBJECTIVE
To assess the effectiveness and safety of multidrug...
Conference Material
|Poster
2018-05-20 • MSF Scientific Days International 2018: Research
2018-05-20 • MSF Scientific Days International 2018: Research
Journal Article
|Research
2021-01-04 • Open Forum Infectious Diseases
2021-01-04 • Open Forum Infectious Diseases
We assessed effectiveness and safety of concomitant chronic hepatitis C virus (HCV) treatment with direct-acting antivirals (DAAs) and multidrug-resistant tuberculosis (MDR-TB). Of 322 M...